You are here

Sangamo

Sangamo scraps public offering ‘after evaluating market conditions’

Endpoints

Sun, 03/5/23 - 03:28 pm

Fulcrum's clinical hold caps off tough week for sickle cell drug development

Fierce Biotech

Sun, 02/26/23 - 10:20 pm

Fulcrum Therapeuticsl

sickle cell disease

clinical trials

In five patients, Sangamo’s Fabry disease gene therapy appears to be working so far

Endpoints

Tue, 08/30/22 - 06:08 pm

Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset

Fierce Biotech

Thu, 10/28/21 - 10:40 am

Sangamo R&D chief hits the exit as it splits R&D into separate units

Fierce Biotech

Thu, 06/25/20 - 10:35 am

Sangamo keeps pressure on rivals with updated hemophilia data

Biopharma Dive

Sat, 12/7/19 - 11:48 pm

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Endpoints

Mon, 07/8/19 - 08:13 pm

Sangamo backs up early success for hemophilia gene therapy

Biopharma Dive

Sat, 07/6/19 - 01:36 pm

Spark Therapeutics

2018 in review: How patient centricity led to new drugs that tackle unmet need

Pharmaforum

Mon, 12/17/18 - 09:22 am

drug development

SEC charges former Sangamo exec, others with insider trading

Biopharma Dive

Fri, 08/24/18 - 10:30 pm

insider trading

Sangamo shares surge 3.4% on $12 mln ALS gene therapy collaboration with Pfizer

Marketwatch

Wed, 01/3/18 - 10:06 am

drug development

The 3 Best Biotech Stocks of 2017

Motley Fool

Sun, 12/17/17 - 10:28 am

Sangamo claims a major milestone in gene editing, treating first patient with its zinc finger nuclease tech

Endpoints

Wed, 11/15/17 - 11:06 am

Hunter Syndrome

Sangamo to transfer two gene therapies to Biogen spin-off

BioPharma Dive

Thu, 12/1/16 - 04:24 pm

sickle cell disease

beta-thalassemia

Shire and Sangamo break up their gene-editing partnership

Fierce Biotech

Wed, 09/2/15 - 12:39 pm

Why Sangamo Was Smart To Buy Ceregene

TheStreet.com

Thu, 09/12/13 - 10:19 am